AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04176133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Study NCT03428464 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
Study NCT03470792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcirculation examination
Description: Sublingual microcirculation images were recorded using an incident dark-field video microscope
Study NCT03470792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcirculation examination
Description: Sublingual microcirculation images were recorded using an incident dark-field video microscope
Study NCT01544504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
Study NCT04176133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Influenza vaccine
Description: Intramuscular (IM) single dose administration. Fluzone, high-dose split virion influenza virus vaccine, Sanofi Pasteur
Study NCT04404621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE) training and computer-based brain (CBB)
Description: 18 weeks of PE and CBB.
Study NCT00003534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02250521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC enhanced direct laryngoscope
Description: The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
Study NCT03656484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline-Metronidazole (TM) group
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
Study NCT03656484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM-Melatonin-Hyaluronic acid (TM-MHa) group
Description: Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
Study NCT00289770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix™
Description: Intramuscular injection, 3 doses
Study NCT01905579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracentesis of the anterior chamber
Description: Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
Study NCT04328558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clavipectoral fascia plane block group
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT03200301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intact Umbilical Cord Milking
Description: Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
Study NCT01973894 — intervention group
Intervention type: PROCEDURE
Intervention: Blood and urine sampling
Description: Blood and urine sampling will follow this schedule:~* 24h: blood (3ml)~* 48h: blood (3ml) and urine~* End of infusion: blood (3ml)~* 6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations.
Study NCT00861796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYR-101
Description: Experimental arm
Study NCT01380691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Description: Administered orally
Study NCT02651688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Study NCT02651688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enclomiphene
Description: Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Study NCT02084914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial scratching
Description: Group A: pipelle Group B: sound
Study NCT02084914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratching
Description: Group A: pipelle Group B: sound
Study NCT03582319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
Study NCT03582319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
Study NCT01590849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraceptives, Oral, Combined (Yaz®)
Description: After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use.
Study NCT00815334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic subureteric injection
Description: Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
Study NCT00815334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic subureteric injection
Description: Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
Study NCT03284112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Old SCHOOL Hip-Hop
Description: A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy.
Study NCT03284112 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: My Plate
Description: The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program.
Study NCT03717168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone
Description: All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
Study NCT03717168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: All patients will not receive growth hormone.
Study NCT01200485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2.
Study NCT04291365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood pressure measurement
Description: Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
Study NCT01200485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
Study NCT02379273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus Hybrid L24 Implant
Description: Subjects have already been implanted with the Nucleus Hybrid L24 implant.
Study NCT03710369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo pill was compounded by McDonalds Pharmacy.
Study NCT03710369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
Study NCT01438840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avatrombopag
Study NCT01438840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Study NCT01438840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01438840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Study NCT01438840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Study NCT01438840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.
Study NCT03062345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-User Virtual Reality Upper Extremity Therapy
Description: Virtual Reality games with the user as the only person required for participation
Study NCT03062345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-User Virtual Reality Upper Extremity Therapy
Description: Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
Study NCT03004586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-Gauge Needle
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
Study NCT03004586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-Gauge Needle
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
Study NCT03004586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)
Description: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
Study NCT00025662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RFT5-SMPT-dgA
Description: A specific anti-interleukin-2 receptor immunotoxin
Study NCT00025662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isolex system
Description: CD34 selection/ T cell depletion used this system
Study NCT04021082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
Study NCT02184299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Study NCT02184299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT02184299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02569632 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Description: All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
Study NCT02548676 — intervention group
Intervention type: DEVICE
Intervention: Optical angiography based on OCT
Description: This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
Study NCT02420405 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Routine gene testing
Description: For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
Study NCT02420405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing
Description: For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
Study NCT00620633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1-sensitized T cells
Description: Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
Study NCT03575195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 550mg orally
Study NCT03575195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT03845023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036 Dose 1
Description: AD036 Dose 1 oral capsule administered before sleep
Study NCT03710369 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
Study NCT02109406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115 Dose 1
Description: AZD 2115, Dose 1 administered as two inhalations BID
Study NCT02109406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 2115, Dose 2
Description: AZD 2115, Dose 2 administered as two inhalations BID
Study NCT02109406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo MDI administered as two inhalations BID
Study NCT03845023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036 Dose 2
Description: AD036 Dose 2 oral capsule administered before sleep
Study NCT03845023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD036 Dose 3
Description: AD036 Dose 3 oral capsule administered before sleep
Study NCT03845023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule administered before sleep
Study NCT03845023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule administered before sleep
Study NCT01795859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
Study NCT01795859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets are identical in appearance to SD-809 tablets.
Study NCT04061070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation with mix of threalose plus polyphenols
Description: The patients will be treated with a mix of trehalose plus polyphenols for 60 days
Study NCT04061070 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Supplementation with mix of threalose plus polyphenols
Description: The patients will not be treated with a mix trehalose plus polyphenols for 60 days
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan